Clinical Trial

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

Study acronym: ASPIRE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-05.
Status change: Not Yet Recruiting → Recruiting 2026-07-06
Trial Details
NCT Number NCT07018947
Lead Sponsor Fundacion Clinic per a la Recerca Biomédica
Conditions Resectable Hepatocellular Carcinoma
Enrollment 90 participants
Start Date 2026-06-02
Primary Completion 2031-06 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-08